Afuco™ Anti-CGRP ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-428CQ) (CAT#: AFC-TAB-428CQ)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CGRP. It is a humanized monoclonal antibody that can be potentially used in the treatment of Migraine. It binds to and inhibits the activity of CGRP.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Humanized
- Type
- ADCC enhanced antibody
- Specificity
- Human CALCA and CALCB
- Species Reactivity
- Human
- Applications
- ELISA, IHC, FC, IP, IF, Inhib
- Conjugate
- Unconjugated
- Generic Name
- Fremanezumab
- Related Disease
- Migraine
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- CALCA; calcitonin related polypeptide alpha; CT; KC; PCT; CGRP; CALC1; CGRP1; CGRP-I
- Gene ID
- 796
- UniProt ID
- P01258
Related Resources
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Fremanezumab"
DrugMonitor™ Anti-Fremanezumab Antibody (VS-1224-YC489)Fremanezumab is a humanized monoclonal antibody targeting human calcitonin gene-related peptide (CGRP) for migraine headache prevention. The DrugMonitor™ Anti-Fremanezumab Antibody (VS-1224-YC489) is an anti-drug antibody (ADA) against Fremanezumab. This drug-based antibody is raised in mice immunized with the Fremanezumab. The anti-Fremanezumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Fremanezumab in samples.
See other products for "CALCA and CALCB"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-425CQ | Afuco™ Anti-CGRP ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-425CQ) | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
AFC-TAB-429CQ | Afuco™ Anti-CGRP ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-429CQ) | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-TAB-428CQ. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: ELISA, IP, FC, FuncS, Neut, IF, WB
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: ELISA, Neut, IF, IP, FC, FuncS
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: IHC, ELISA, FC, WB, ADCC, FuncS
Application: WB, ELISA
Application: WB, ELISA, Neut, FuncS
Application: ELISA, WB
Application: WB, ELISA, FuncS
Application: ELISA, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.